Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Collyar: What's In It for Patients?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Nov
20
Today In Oncology
Melanoma Cancer Cluster Found in Parts of Pennsylvania
FDA Grants Accelerated Approval to Sevabertinib for Nonsquamous NSCLC
Patient Immune System Characteristics and Long-Term Remission From CAR T-Cell Therapy in Multiple Myeloma
Vorasidenib in IDH1/2-Mutant Low-Grade Glioma
New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo